液体活检在肝细胞癌临床管理中的应用
综述总结液体活检在肿瘤学领域的最新进展,并详述其在肝细胞癌临床管理中的潜在应用。循环肿瘤DNA甲基化谱分析已成为高危人群早期肝细胞癌检测的有前景监测工具,可能很快改变监测项目的实施方式。文章还概述了不同液体活检技术的技术特点,以帮助非专家解读。
要点
- 液体活检分析循环肿瘤成分,包括循环肿瘤DNA、肿瘤细胞或肿瘤来源细胞外囊泡。
- 肝细胞癌组织标本获取多限于早期患者,液体活检可能尤为有用。
- 循环肿瘤DNA甲基化谱分析已成为高危人群早期肝细胞癌检测的有前景监测工具。
核心结论
- 循环肿瘤DNA甲基化谱分析已发展为高危人群早期肝细胞癌检测的有前景监测工具,可能很快改变监测项目的实施方式。
研究设计与样本
- 综述,总结液体活检在肿瘤学领域的最新进展及其在肝细胞癌临床管理中的潜在意义。
主要发现
- 多种基于血液的突变谱检测已商业化并进入临床领域。
- 已开展多种转化性液体活检研究,以满足早期肝细胞癌检测和治疗反应预测等临床需求。
- 循环肿瘤DNA甲基化谱分析已成为高危人群早期肝细胞癌检测的有前景监测工具。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With increasing knowledge on molecular tumour information, precision oncology has revolutionised the medical field over the past years. Liquid biopsy entails the analysis of circulating tumour components, such as circulating tumour DNA, tumour cells or tumour-derived extracellular vesicles, and has thus come as a handy tool for personalised medicine in many cancer entities. Clinical applications under investigation include early cancer detection, prediction of treatment response and molecular monitoring of the disease, for example, to comprehend resistance patterns and clonal tumour evolution. In fact, several tests for blood-based mutation profiling are already commercially available and have entered the clinical field.In the context of hepatocellular carcinoma, where access to tissue specimens remains mostly limited to patients with early stage tumours, liquid biopsy approaches might be particularly helpful. A variety of translational liquid biopsy studies have been carried out to address clinical needs, such as early hepatocellular carcinoma detection and prediction of treatment response. To this regard, methylation profiling of circulating tumour DNA has evolved as a promising surveillance tool for early hepatocellular carcinoma detection in populations at risk, which might soon transform the way surveillance programmes are implemented. This review summarises recent developments in the liquid biopsy oncological space and, in more detail, the potential implications in the clinical management of hepatocellular carcinoma. It further outlines technical peculiarities across liquid biopsy technologies, which might be helpful for interpretation by non-experts.
引用
- von Felden J, Garcia-Lezana T, Schulze K, et al. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut. 2020. PMID: 32883873. doi:10.1136/gutjnl-2019-320282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。